Mexidol: analogues in composition and mechanism of action, in tablets and ampoules - cheap, imported. Best information! Instructions for use and dosage regimen

Antioxidant drug

Active substance

Ethylmethylhydroxypyridine succinate

Release form, composition and packaging

Capsules hard gelatin, size No. 2, yellow color; the contents of the capsules are granules containing granules and powder that are white or white with a yellowish tint.

Excipients: potato starch - 54.5 mg, (medical low molecular weight polyvinylpyrrolidone 12600±2700) - 4 mg, lactose (milk sugar) - 40 mg, magnesium stearate - 0.5 mg, microcrystalline cellulose - 1 mg.

Composition of hard gelatin capsule No. 2: gelatin - 59.3189 mg, titanium dioxide (E171) - 1.22 mg, sunset yellow dye (E110) - 0.0036 mg, quinoline yellow dye (E104) - 0.4575 mg.

10 pieces. - contour cell packaging (2) - cardboard packs.
10 pieces. - contour cell packaging (3) - cardboard packs.
10 pieces. - contour cell packaging (6) - cardboard packs.

pharmachologic effect

Pharmacodynamics

Antioxidant drug. Ethylmethylhydroxypyridine succinate has antioxidant, antihypoxic, anti-ischemic, membrane-protective, nootropic, stress-protective, anticonvulsant, and anxiolytic effects.

The drug helps increase the body's resistance to the effects of various damaging factors, with oxygen-dependent pathological conditions(shock, hypoxia and ischemia, disorders cerebral circulation, IHD, ethanol intoxication and condition after intoxication antipsychotics). The drug reduces the manifestations of oxidative stress, inhibits free radical processes of lipid peroxidation, and increases the activity of superoxide dismutase. Modulates the activity of membrane-bound enzymes - calcium-independent PDE, adenylate cyclase, acetylcholinesterase, receptor complexes (benzodiazepine, gamma-aminobutyric, acetylcholine), which enhances their ability to bind to ligands and helps maintain the structural and functional organization biological membranes, improves neurotransmitter transport and synaptic transmission. Increases content in the brain.

The drug causes an increase in the compensatory activity of aerobic glycolysis and helps reduce the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of adenosine triphosphate, creatine phosphate and activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes.

In patients stable angina tension increases tolerance to physical activity and antianginal activity of nitro drugs, improves rheological properties blood. Adding Mexicor to standard therapy for coronary artery disease improves clinical condition patients, increasing tolerance to physical activity and improving quality of life.

The energy-synthesizing effect of the drug Mexicor is associated with an increase in the delivery and consumption of succinate by cells and the implementation of the phenomenon of rapid oxidation succinic acid succinate dehydrogenase, as well as with activation of the mitochondrial respiratory chain. When ethylmethylhydroxypyridine succinate dissociates in a cell into succinate and a 3-hydroxypyridine derivative (base), the base exhibits an antioxidant effect, stabilizing cell membranes and restoring functional activity cells.

The drug improves functional state ischemic myocardium during, improves the contractile function of the heart, and also reduces the manifestations of systolic and diastolic dysfunction of the left ventricle. Normalizes metabolic processes in the ischemic myocardium, reduces the necrosis zone, restores the electrical activity and contractility of the myocardium, and also increases its collateral blood supply, activating energy-synthesizing processes in the ischemic zone and helping to preserve the integrity of cardiomyocytes and maintain their functional activity. Effectively restores myocardial contractility during reversible cardiac dysfunction, which represents a significant reserve for increasing cardiac contractility in patients with coronary artery disease.

In patients with stable angina pectoris, it increases exercise tolerance and the antianginal activity of nitro drugs, improves the rheological properties of blood, reduces platelet aggregation and the consequences of reperfusion syndrome in acute coronary insufficiency. Has a hypolipidemic effect, reduces the content total cholesterol and LDL.

Improves blood supply to the brain and cerebral metabolism, improves blood microcirculation, prevents a decrease in cerebral blood flow during the reperfusion period after ischemia. Prevents a post-ischemic drop in brain utilization and oxygen, and prevents the progressive accumulation of lactate. The drug has a selective anxiolytic effect, not accompanied by sedation and muscle relaxation, eliminates anxiety, fear, tension, restlessness, increases adaptation and emotional status.

The effectiveness of the drug under stressful conditions is manifested in the normalization of post-stress behavior, psycho-vegetative disorders, restoration of sleep-wake cycles, mnestic functions, learning processes, reduction structural changes brain substances. The drug is characterized by a pronounced antitoxic effect in withdrawal syndrome. Eliminates neurological manifestations acute alcohol intoxication, restores behavioral disorders, autonomic functions, and is also able to reduce cognitive impairment caused by long-term ethanol intake. Under the influence of ethylmethylhydroxypyridine succinate, the effect of tranquilizing, neuroleptic, antidepressant, hypnotic and anticonvulsants, which allows you to reduce their doses and reduce side effects.

Pharmacokinetics

Suction

Rapidly absorbed when taken orally. Cmax in the blood at doses of 400-500 mg is 3.5-4 mcg/ml.

Distribution

Quickly distributed in organs and tissues. The average time of distribution of the drug in the body when taken orally is 4.9-5.2 hours.

Metabolism

Metabolized in the liver by glucuronidation. 5 metabolites have been identified: 3-hydroxypyridine phosphate - is formed in the liver and, with the participation of alkaline phosphate, breaks down into phosphoric acid and 3-hydroxypyridine; 2nd metabolite - pharmacologically active, formed in large quantities and is detected in urine 1-2 days after taking the drug; 3rd - excreted in large quantities by the kidneys; 4th and 5th - glucuron conjugates.

Removal

T1/2 when taken orally is 2-2.6 hours. It is quickly excreted in the urine, mainly in the form of metabolites and in small quantities unchanged. The most intensive elimination occurs during the first 4 hours after taking the drug. Urinary excretion rates of unchanged drug and metabolites have high individual variability

Indications

— IHD (as part of complex therapy);

- consequences of acute cerebrovascular accidents, incl. after transient ischemic attacks, in the subcompensation phase, as preventive courses;

- mild traumatic brain injury, consequences of traumatic brain injury;

— encephalopathy of various origins(dyscirculatory, dysmetabolic, post-traumatic, mixed);

- functional disorders of the autonomic nervous system(syndrome vegetative dystonia);

— mild cognitive disorders of atherosclerotic origin;

— anxiety disorders for neurotic and neurosis-like conditions;

— relief of withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders, post-withdrawal disorders;

— conditions after acute intoxication with antipsychotic drugs;

— asthenic conditions, as well as to prevent the development somatic diseases under the influence of extreme factors and loads;

— exposure to extreme (stress) factors.

Contraindications

— increased sensitivity to the active substance or other components of the drug;

- spicy liver failure;

- spicy renal failure;

— childhood up to 18 years of age (the safety and effectiveness of the drug in children have not been studied);

- pregnancy;

- period breastfeeding;

- rare hereditary galactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome (the drug contains lactose).

Carefully: impaired liver function, impaired renal function (limited experience of medical use).

Dosage

IHD (as part of complex therapy)

Begin treatment with a dose of 100 mg (1 capsule) 1-2 times a day, if necessary, gradually increasing the dose depending on therapeutic effect and tolerability of the therapy. The maximum daily dose should not exceed 800 mg (eight capsules), a single dose - 200 mg. Daily dose The drug should be distributed into 2-3 doses during the day. The course of treatment with Mexicor is completed gradually, reducing the daily dose of the drug by 100 mg (1 capsule).

Typically, the duration of treatment with Mexicor when used is as part of complex therapy for ischemic heart disease is at least 1.5-2 months. However, the dose of the drug, the duration of the course of treatment and the need for repeated courses of therapy must be individually determined by the doctor, based on the therapeutic effect and tolerability of the drug.

Consequences of acute cerebrovascular accidents; mild traumatic brain injury, consequences of traumatic brain injury; encephalopathy of various origins; functional disorders of the autonomic nervous system; mild cognitive disorders of atherosclerotic origin; anxiety disorders in neurotic and neurosis-like conditions; conditions after acute intoxication with antipsychotic drugs; asthenic conditions; exposure to extreme (stress) factors

Treatment is started with a dose of 100 mg (1 capsule) 1-2 times a day, if necessary, gradually increasing the dose depending on the therapeutic effect and tolerability of the therapy. The maximum daily dose should not exceed 800 mg (eight capsules), the maximum single dose is 200 mg (two capsules). The daily dose of the drug should be distributed into 2-3 doses during the day. Treatment with Mexicor is stopped gradually, reducing the dose of the drug by 100 mg (1 capsule) daily.

Typically, the duration of treatment with Mexicor for the above indications for use is 2-6 weeks. However, the dose of the drug and the duration of treatment must be individually determined by the doctor, based on the therapeutic effect and tolerability of the drug.

Relief of withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders, post-withdrawal disorders

Treatment is started with a dose of 100 mg (1 capsule) 1-2 times a day, if necessary, gradually increasing the dose depending on the therapeutic effect and tolerability of the therapy. The maximum daily dose should not exceed 800 mg (eight capsules), the maximum single dose is 200 mg (two capsules). The daily dose of the drug should be distributed into 2-3 doses during the day. Treatment with Mexicor is discontinued gradually, reducing the dose over 2-3 days.

Typically, the duration of treatment with Mexicor for the purpose of relieving withdrawal symptoms in alcoholism is 5-7 days. However, the dose of the drug and the duration of treatment must be individually determined by the doctor, based on the therapeutic effect and tolerability of the drug.

Side effects

Maybe: allergic reactions (including systemic allergic reactions), dyspeptic symptoms (nausea, dry mouth, diarrhea), which quickly disappear on their own or when the drug is discontinued.

With long-term use: Possible flatulence, sleep disturbances (drowsiness or difficulty falling asleep).

Overdose

Due to the low toxicity of the drug, an overdose is unlikely. There is no information on cases of drug overdose.

Symptoms: In case of an overdose, symptoms of sleep disturbance may occur - drowsiness, insomnia.

Treatment: carry out symptomatic therapy.

Drug interactions

Mexicor enhances the effect of benzodiazepine anxiolytics, antidepressants, anticonvulsants and antiparkinsonian drugs (levodopa).

Mexicor increases the antianginal activity of nitro drugs and enhances the hypotensive effect of ACE inhibitors and.

Mexicor reduces the toxic effects of ethanol.

Before prescribing Mexicor, the patient's medical history should be carefully collected to assess the potential for drug interactions.

special instructions

In patients with impaired renal or hepatic function, the drug should be used with caution, with periodic monitoring of renal and liver function indicators.

Due to the presence in the composition medicinal product Mexicor lactose, the use of the drug is contraindicated in patients with rare hereditary galactose intolerance, lactase deficiency, glucose-galactose malabsorption.

The drug as part of the excipients contains dyes and may cause the development allergic reactions(including system ones). If signs of an allergic reaction appear, use of the drug should be stopped immediately.

Effect on ability to drive vehicles and mechanisms

During treatment with the drug, caution must be exercised when driving vehicles and engaging in other potentially dangerous activities. dangerous species activities requiring increased concentration attention and speed of psychomotor reactions.

For liver dysfunction

Contraindicated in acute liver dysfunction.

Conditions for dispensing from pharmacies

The drug is available with a prescription.

Storage conditions and periods

The drug should be stored out of the reach of children, in a dry place, protected from light, at a temperature not exceeding 25°C. Shelf life – 3 years.

One capsule contains active substance:hydroxymethylethylpyridine succinate – 0.1 g, and also Excipients – succinic acid, milk sugar, potato starch and magnesium stearate.

2 ml ampoules contain oxymethylethylpyridine succinate – 100 mg, Trilon B and water for injection.

Release form

The medicine is produced in capsules of 0.1 g of active substance and ampoules of 2 ml, which contain 50 mg/ml of the main component.

pharmachologic effect

Mexico has antihypoxic, neuroprotective, nootropic, anxiolytic and antioxidant effects .

Pharmacodynamics and pharmacokinetics

When treated with this drug, the manifestations of oxidative stress are reduced, free radical lipid peroxidation is inhibited and the activity of the antioxidant enzyme system is increased. Cellular energy exchange also improves, the energy-synthesizing functions of mitochondria and compensatory activation of aerobic glycolysis are activated, and the degree of inhibition of oxidative processes is reduced.

In addition, there was an improvement in cerebral metabolism and blood supply to the brain, microcirculation and rheological properties of blood, a decrease in platelet aggregation, and so on.

Absorption of the active substance inside the body occurs from the gastrointestinal tract quickly and completely. The maximum concentration in blood plasma is achieved within an hour. At the same time, the drug is distributed quite quickly in tissues and organs.

Mexicor is excreted primarily in the form of a glucuronoconjugate in the urine. The most active process was observed during the first 4 hours from the moment of taking the drug.

Indications for use of Mexicor

The drug in capsules is prescribed in complex therapy for:

• ischemic stroke;
• mild to moderate cognitive disorders regardless of origin;

Contraindications for use

• acute disorders liver and kidney activity;
• the age of patients is under 18 years, since the effect of the drug has not been established;
• , ;
• sensitivity or intolerance to the components of the drug.

Side effects

When treated with Mexicor, you may suffer digestive system which is accompanied , dry mouth, nausea,. Usually these symptoms go away on their own after stopping the drug. Long-term use the drug often leads to

Sleep problems and development are also possible. .

Mexicor - instructions for use (Method and dosage)

Medicine in ampoules intended for intravenous drip or intramuscular injection. The course of treatment against the background of the main drug therapy acute myocardial infarction is 14 days. To obtain a quick therapeutic effect, it is recommended to administer the drug intravenously in the first 5 days, then switch to intramuscular use.

Intravenous drip administration should be performed quite slowly using saline solution sodium chloride or 5% glucose solution by volume. For example, 100-150 ml of solution should be administered over 30-90 minutes. You can also give injections, and a slow stream intravenous injection is allowed, which is carried out for at least 5 minutes.

According to the instructions for use Mexicora in tablets, they should be taken every 8 hours, 3 times a day. The average single dosage is 2-3 mg per kg of weight, and the daily dosage is 6-9 mg per kg of weight. The permissible maximum single dose is 0.25 g, and the daily dose is 0.8 g. Capsules are usually prescribed orally as part of complex therapy.

For each disease, the treatment regimen and the required dosage of the drug are determined by the doctor. This takes into account the nosological form of the disease and the patient’s individual sensitivity to the drug. The duration of treatment with Mexicor may also vary, for example, with coronary disease heart and cerebrovascular accidents it is 1.5-2 months.

Treatment with Mexicort should be ended gradually, reducing the daily dosage by 0.1 g.

Overdose

In case of an overdose of this drug, symptoms may appear, slight increase blood pressure. Such cases do not require special therapy, as they usually go away on their own.

If there is a significant increase in blood pressure, then tablets are prescribed to lower it, in addition to antianginal drugs.

Interaction

Taking Mexicor capsules and injections enhances the effect of antiparkinsonian and anticonvulsant drugs, as well as benzodiazepine anxiolytics. In addition, the activity of antianginal drugs increases, the hypotensive effect of beta-blockers, ACE inhibitors and the effect of antiarrhythmic drugs increases.

Terms of sale

The drug is available with a prescription.

Storage conditions

The storage place should be dry, dark and protected from children, with a temperature of up to 25°C.

Best before date

Mexico's analogues

Level 4 ATX code matches:

It should be noted that Mexicor and its analogues have the same active substance, and, therefore, indications for use. Therefore these include: Medomexi, Meksidant, Mexipridol.

Alcohol and Mexicor

Because this medicine can be used for cupping alcohol withdrawal syndrome, then the consumption of alcoholic beverages during treatment with Mexico is not prohibited.

Reviews about Mexicor

This drug, like its analogues, is often discussed on medical forums. At the same time, doctors’ reviews about Mexicor are no less varied, as are the opinions of patients. Often, professionals report that when treated with this medicine no noticeable effects are observed. In addition, some experts have doubts about the effectiveness of the composition of the drug and its metabolites - components that are formed after the breakdown of the drug in the human body. Therefore, they argue that with mono-treatment with Mexicor one should not expect much beneficial influence on health status.

Regarding patients' opinions about this drug, then many of them really say that treatment with Mexicor did not have any effect on the body.

Mexico price, where to buy

Medicine of any form can be purchased in pharmacies in Moscow and other Russian regions. At the same time, the price of Mexicor in tablets is offered from 122 rubles, 2 ml ampoules from 265 rubles.

You can buy capsules in Kyiv for 94.40 UAH, 2 ml ampoules for 253.55 UAH.

• Online pharmacies in Russia Russia
• Online pharmacies in Ukraine Ukraine

Analogs of the drug Mexicor are presented, in accordance with medical terminology, called “synonyms” - drugs that are interchangeable in their effects on the body, containing one or more identical active ingredients. When selecting synonyms, consider not only their cost, but also the country of production and the reputation of the manufacturer.

Description of the drug

List of analogues

Note! The list contains synonyms for Mexicor, which have a similar composition, so you can choose a replacement yourself, taking into account the form and dose of the medicine prescribed by your doctor. Give preference to manufacturers from the USA, Japan, Western Europe, as well as well-known companies from of Eastern Europe: KRKA, Gedeon Richter, Actavis, Aegis, Lek, Hexal, Teva, Zentiva.

Reviews

Visitor survey results

Eight visitors reported effectiveness

Ten visitors reported cost estimates

Twenty visitors reported frequency of intake per day

Fifteen visitors reported dosage

Three visitors reported an expiration date

Four visitors reported appointment times

76 visitors reported the patient's age

Visitor reviews

Official instructions for use

Mexicor®

Pharmacological properties

Indications for use

Contraindications

Directions for use and doses

Side effects

Overdose

Interaction with other drugs

special instructions

Release form

Storage conditions

Best before date

Vacation conditions

The information on the page was verified by physician-therapist E.I. Vasilyeva.

International name

Group affiliation

Dosage form

pharmachologic effect

An inhibitor of free radical processes is a membrane protector, which also has antihypoxic, stress-protective, nootropic, antiepileptic and anxiolytic effects.

The mechanism of action is due to antioxidant and membrane protective properties. Suppresses lipid peroxidation, increases superoxide oxidase activity, increases the lipid-protein ratio, reduces membrane viscosity, and increases its fluidity. Modulates the activity of membrane-bound enzymes (Ca2+-independent PDE, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which promotes their binding to ligands, preservation of the structural and functional organization of biomembranes, transport of neurotransmitters and improvement of synaptic transmission. Increases the concentration of dopamine in the brain. Causes an increase in compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes.

Increases the body's resistance to the effects of various damaging factors in pathological conditions (shock, hypoxia and ischemia, cerebrovascular accidents, intoxication with ethanol and antipsychotic drugs).

Improves metabolism and blood supply to the brain, microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes the membranes of blood cells (erythrocytes and platelets), reducing the likelihood of hemolysis. It has a lipid-lowering effect, reduces the content of total cholesterol and LDL. Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.

Indications

Inside: neurotic and neurosis-like states (anxiety, fear, irritability, emotional lability, VSD); organic psychosyndrome caused by cerebrovascular accident; encephalopathy; TBI; intellectual-mnestic disorders (of various origins, including memory impairment in the elderly); withdrawal syndrome.

Parenteral: acute cerebrovascular accident; psychoorganic syndrome caused by cerebrovascular accident; encephalopathy; VSD; intellectual-mnestic disorders (including memory impairment in the elderly); TBI; neurotic and neurosis-like states (anxiety, fear, irritability, emotional lability); intoxication caused by antipsychotic drugs; withdrawal syndrome; acute purulent-inflammatory processes in abdominal cavity (acute pancreatic necrosis, peritonitis) as part of complex therapy.

Contraindications

Side effects

Nausea, dry mouth, drowsiness, allergic reactions.

Application and dosage

Orally, 0.25-0.5 g/day in 2-3 divided doses; maximum daily dose – 0.6-0.8 g. Duration of treatment – ​​2-6 weeks; to relieve alcohol withdrawal – 5-7 days. Treatment is stopped gradually.

IM, IV (stream, for 5-7 minutes or drip, at a speed of 60 drops/min). The initial dose is 0.05-0.1 g 1-3 times a day with a gradual increase until a therapeutic effect is obtained. The maximum daily dose is 0.8 g.

In case of acute cerebrovascular accident - intravenous drip, 0.2-0.3 g once a day in the first 2-4 days, then intramuscularly, 0.1 g 3 times a day.

For discirculatory encephalopathy - intravenously in a stream or drip, 0.1 g 2-3 times a day for 14 days, and then intramuscularly, 0.1 g for 14 days. For course prophylaxis of discirculatory encephalopathy - intramuscularly, 0.1 g 2 times a day for 10-14 days.

VSD – intramuscularly, 0.05-0.1 g 3 times a day.

For withdrawal syndrome - IM, 100-200 mg 2-3 times a day or IV drip, 1-2 times a day for 5-7 days.

For neurotic and neurosis-like disorders - intramuscularly, 0.05-0.4 g/day.

For memory and intellectual disorders - intramuscularly, 0.1-0.3 g/day for 14-30 days.

For acute intoxication with antipsychotic drugs - IV, 0.05-0.3 g/day for 7-14 days.

In acute purulent-inflammatory processes of the abdominal cavity, it is prescribed on the first day both preoperatively and during postoperative period. Doses depend on the form and severity of the disease, the prevalence of the process, and variations in its course. The drug is discontinued gradually, after a stable positive clinical and laboratory effect.

For acute edematous (interstitial) pancreatitis - intravenous drip and intramuscular injection, 0.1 g 3 times a day. Mild degree severity of pancreatic necrosis - intravenous drip and intramuscular injection, 100-200 mg 3 times a day. Average degree severity - intravenous drip, 0.2 g 3 times a day. Severe course - 0.4 g 2 times a day, then 0.3 g 2 times a day with a gradual decrease in the daily dose. Extremely severe course– 0.8 g/day until persistent relief of the manifestations of pancreatogenic shock, when the condition stabilizes – intravenously, 0.3-0.4 g 2 times a day with a gradual decrease in the daily dose.

special instructions

When administered by infusion, it is diluted in a 0.9% NaCl solution.

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Interaction

Enhances the effect of benzodiazepine anxiolytics, antiepileptic (carbamazepine), antiparkinsonian (levodopa) drugs.

Reduces the toxic effects of ethanol.

Reviews of the drug Mexicor: 0

Write your review

Hard gelatin capsules - 1 capsule. ethylmethylhydroxypyridine succinate (in terms of 100% substance) - 100 mg excipients: potato starch; povidone (low molecular weight medical PVP 12600±2700); lactose (milk sugar); magnesium stearate; MCC in blister packaging 10 pcs.; in a cardboard pack 2 or 5 packs.

Description of the dosage form

Hard gelatin capsules No. 2, yellow. The contents of the capsules are granulates containing granules and powder that are white or white with a yellowish tint.

Pharmacokinetics

After oral administration, it is quickly and completely absorbed from the gastrointestinal tract. Quickly distributed in organs and tissues. Tmax in blood plasma is 0.46-0.5 hours. The average distribution time of the drug in the body is 4.9-5.2 hours. Metabolized in the liver by glucuronidation. T1/2 - 4.7-5 hours. On average, in 12 hours the following is excreted by the kidneys (from the administered dose): 0.3% - unchanged and 50% - in the form of glucuronoconjugate. The most intense elimination occurs during the first 4 hours after taking the drug. The rates of renal excretion of unchanged drug and metabolites have significant individual variability.

Pharmacodynamics

Mexicor® reduces the manifestations of oxidative stress by inhibiting free radical lipid peroxidation and increasing the activity of the antioxidant enzyme system. Improves cellular energy metabolism, activating the energy-synthesizing functions of mitochondria, enhancing compensatory activation of aerobic glycolysis and reducing the degree of inhibition of oxidative processes in the Krebs cycle. The energy-synthesizing effect of the drug is associated with an increase in the delivery and consumption of succinate by cells, the implementation of the phenomenon of rapid oxidation of succinic acid by succinate dehydrogenase, as well as with the activation of the mitochondrial respiratory chain. When the drug Mexicor® dissociates in the cell into succinate and a 3-hydroxypyridine derivative (base), the base exhibits an antioxidant effect that stabilizes cell membranes and restores the functional activity of cells. The action of the drug is based on its antioxidant activity, the ability to inhibit free radical processes (pronounced intensification of which is observed during myocardial ischemia and necrosis, especially during the period of reperfusion) and reduces the damaging effect of free radicals on cardiomyocytes. Reduces viscosity cell membrane, increases its fluidity and has a modulating effect on membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), ion channels and receptor complexes, which helps maintain the structural and functional integrity of biomembranes, improves the transport of neurotransmitters and synaptic transmission. Improves metabolism and blood supply to the brain, microcirculation and rheological properties of blood, reduces platelet aggregation. Improves the functional state of ischemic myocardium, contractile function of the heart, and also reduces the manifestations of systolic and diastolic dysfunction of the left ventricle. In conditions of coronary insufficiency, it increases collateral blood supply to the ischemic myocardium and activates energy-synthesizing processes in the ischemic zone, which helps preserve the integrity of cardiomyocytes and maintain their functional activity. Effectively restores myocardial contractility during reversible cardiac dysfunction, which represents a significant reserve for increasing cardiac contractility in patients with coronary artery disease complicated by heart failure. In patients with stable angina pectoris, it increases tolerance to physical activity and the antianginal activity of nitro drugs, improves the rheological properties of blood. The addition of Mexicor® to standard therapy for coronary artery disease improves the clinical condition of patients, increasing exercise tolerance and improving quality of life. Mexicor® stabilizes membrane structures vascular wall, inhibits platelet aggregation, normalizes microcirculation disorders early stages atherogenesis, has a hypolipidemic effect, reduces the content of total cholesterol and low-density lipoproteins (LDL). Mexicor® has a neuroprotective effect on the functional activity and metabolism of the ischemic brain, increases the stability of cerebral circulation in conditions of hypoperfusion, and prevents a decrease in cerebral blood flow during the reperfusion period after ischemia. The drug promotes adaptation to the damaging effects of ischemia by inhibiting the depletion of carbohydrate reserves, blocking the post-ischemic drop in the utilization of glucose and oxygen by the brain and preventing the progressive accumulation of lactate. At the same time, the indicators of autoregulatory reactions of cerebral vessels improve. Mexicor® has nootropic properties, prevents and reduces learning and memory impairments that occur in acute and chronic vascular diseases of the brain, mild and moderate cognitive impairment of various origins, has an antioxidant effect, increases concentration and performance. The inclusion of the drug Mexicor® in complex therapy of patients with acute cerebrovascular accident reduces the severity of clinical manifestations of stroke and improves the course of the rehabilitation period. Mexicor® has a selective anxiolytic effect, not accompanied by sedation and muscle relaxation, eliminates anxiety, fear, tension, restlessness, increases adaptation and emotional status.

Indications for use Mexicor

coronary heart disease (as part of complex therapy); ischemic stroke (as part of complex therapy); encephalopathy; mild to moderate cognitive impairment.

Contraindications to the use of Mexicor

hypersensitivity to the drug; acute dysfunction of the liver and kidneys; age under 18 years (efficacy and safety have not been established); pregnancy; breastfeeding period.

Mexicor Side Effects

Usually the drug is well tolerated. In rare cases, allergic reactions, dyspeptic disorders, dry mouth, and diarrhea may occur, which quickly disappear on their own or when the drug is discontinued. Long-term administration of the drug may cause flatulence and sleep disturbances (drowsiness or difficulty falling asleep).

Drug interactions

Enhances the effect of anticonvulsants (carbamazepine), antiparkinsonian drugs (levodopa) and benzodiazepine anxiolytics. Increases the antianginal activity of nitro drugs. Increases the hypotensive activity of ACE inhibitors and beta-blockers. Reduces the toxic effects of ethanol.

Mexicor dosage

Inside. Begin treatment with a dose of 100 mg (1 capsule) 3 times a day, gradually increasing the dose depending on clinical course disease and tolerability of the therapy. The maximum daily dose should not exceed 800 mg, a single dose - 200 mg. It is advisable to distribute the daily dose of the drug into several doses throughout the day. The course of drug therapy is completed gradually, reducing the daily dose of the drug by 100 mg (1 capsule). The duration of the course of therapy in patients with ischemic heart disease and cerebral circulatory disorders is at least 1.5-2 months. Repeated courses (on the recommendation of a doctor) are preferably carried out in the spring and autumn. For complex therapy of discirculatory encephalopathy, mild and moderate cognitive disorders, the drug is prescribed without limiting the course of treatment in duration at a dose of 100 mg 3-4 times a day.

Overdose

Due to the low toxicity of the drug, an overdose is unlikely. Symptoms: possible sleep disturbance (drowsiness, insomnia). Treatment: symptomatic.